OCS

Oculis Holding AG Ordinary shares

7.59

USD

-0.17

-2.19%

Nov 10, 15:59 UTC -5

Closed

After-Market

7.63

+0.04

+0.46%

Oculis Holding AG Ordinary shares (OCS) Earnings

OCS Earnings Reports

Positive Surprise Ratio

OCS beat 6 of 15 last estimates.

40%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Oculis Holding AG Ordinary shares earnings per share and revenue

On Nov 03, 2026, OCS reported earnings of -0.30 USD per share (EPS) for Q3 26, beating the estimate of -0.42 USD, resulting in a 28.91% surprise. Revenue reached 7.00 thousand, compared to an expected 169.86 thousand, with a -95.88% difference. The market reacted with a -4.59% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Oculis Holding AG Ordinary shares's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Oculis Holding AG Ordinary shares reported EPS of -$0.30, beating estimates by 28.91%, and revenue of $7.00K, -95.88% below expectations.

How did the market react to Oculis Holding AG Ordinary shares's Q3 2026 earnings?

The stock price moved down -4.59%, changed from $7.63 before the earnings release to $7.28 the day after.

When is Oculis Holding AG Ordinary shares expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Oculis Holding AG Ordinary shares's next earnings report?

Based on -- analysts, Oculis Holding AG Ordinary shares is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.